about
P161
Impact of the H275Y and I223V Mutations in the Neuraminidase of the 2009 Pandemic Influenza Virus In Vitro and Evaluating Experimental ReproducibilityA drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progression.A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges aheadExploring cell tropism as a possible contributor to influenza infection severityViral factors in influenza pandemic risk assessment.Higher level of replication efficiency of 2009 (H1N1) pandemic influenza virus than those of seasonal and avian strains: kinetics from epithelial cell culture and computational modelingThe in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patientsThe H275Y neuraminidase mutation of the pandemic A/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets.Kinetics of influenza A virus infection in humans.Exploring the effect of biological delays in kinetic models of influenza within a host or cell cultureAssessing the in vitro fitness of an oseltamivir-resistant seasonal A/H1N1 influenza strain using a mathematical modelAssessing mathematical models of influenza infections using features of the immune response.A method to determine the duration of the eclipse phase for in vitro infection with a highly pathogenic SHIV strain.Modeling amantadine treatment of influenza A virus in vitro.(In)validating experimentally derived knowledge about influenza A defective interfering particles.Duration of SHIV production by infected cells is not exponentially distributed: Implications for estimates of infection parameters and antiviral efficacy.A conservation law for virus infection kinetics in vitro.Quantification system for the viral dynamics of a highly pathogenic simian/human immunodeficiency virus based on an in vitro experiment and a mathematical modelExploring virus release as a bottleneck for the spread of influenza A virus infection in vitro and the implications for antiviral therapy with neuraminidase inhibitors.Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms.Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study.Design considerations in building in silico equivalents of common experimental influenza virus assays.Modelling endurance and resumption times for repetitive one-hand pushing.Information processing mechanisms in microtubules at physiological temperature: Model predictions for experimental tests.Probing the effects of the well-mixed assumption on viral infection dynamics.A simple cellular automaton model for influenza A viral infections.Uncovering critical properties of the human respiratory syncytial virus by combining in vitro assays and in silico analysesCharacterizing T cell movement within lymph nodes in the absence of antigenA mathematical model describing the localization and spread of influenza A virus infection within the human respiratory tract
P50
Q24288661-55FCC023-0676-4A8A-B626-A2EEEFA4F175Q27324423-B1EDC837-6E7F-449C-8EE2-8DD331F92D4BQ28382972-63761BC9-1256-41AD-BC2B-A9C26894AC05Q28748187-81BF8E8A-74EC-41C4-B86C-C77FD442B585Q30275435-B6A54FAA-1C02-4ECD-AE18-F9ABE9329791Q30396110-CB349ACD-8386-4B26-9C12-A1750FE42C60Q30397216-FABD4EDB-8BD5-4A16-8398-41B05105E8CEQ30419738-D8D478D3-C501-4628-A833-87E351648731Q30445615-2C5E95FA-F118-4A8B-9BA8-963D7FFB2922Q33831147-B49D062A-3C44-4AD2-AE36-0763824FBAD6Q33859412-F0EE8F99-E502-4A94-9F66-5982ABFBF4BAQ34611749-039B5FF7-CBDF-45BD-9F19-1843F0F15483Q35633691-2B382831-6BD5-4BEE-9645-80FDFA6B055EQ37145829-A3BD3589-6A2F-42A1-AF46-2EDDF08F8D6FQ37466028-91233711-AAAF-43FA-8641-530376760FCDQ37644303-18167EBD-07CC-4793-8BFE-68E93C8712C9Q38886044-2EE41FBF-7FEB-4850-838C-A175561302F1Q39390501-56AE14AA-8FD9-431A-A4E5-CA3C75632A5BQ40072156-E6DFABB6-E2C1-452E-9521-4665E20D7A11Q40138039-83B932AE-C7E6-4FE7-AA4E-D978E52538ADQ45104651-DDD6018E-98F0-46B7-9267-B746E175478AQ45369770-2618DB5E-E83D-420E-84EE-8B607DD61686Q47565829-EB08B8D5-0E30-4A20-9736-039B910FB6DCQ47706483-B7D6CF5E-6848-4EDB-99E1-99DF28AFF0FCQ47852502-3BF39A07-05A4-4FA0-A7C5-07790EB2DDBAQ47866416-0176B6CB-4E3B-4718-907E-D1975819B8DBQ64115042-C0D5038F-5EF8-4850-85E2-5456D1E4EFF1Q80178350-578FB838-A70E-4F78-B478-2AFE0A1E3EABQ91861040-E5326C4B-5383-43AB-BD12-D443468EE90D
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Catherine Beauchemin
@ast
Catherine Beauchemin
@en
Catherine Beauchemin
@es
Catherine Beauchemin
@nl
type
label
Catherine Beauchemin
@ast
Catherine Beauchemin
@en
Catherine Beauchemin
@es
Catherine Beauchemin
@nl
prefLabel
Catherine Beauchemin
@ast
Catherine Beauchemin
@en
Catherine Beauchemin
@es
Catherine Beauchemin
@nl
P106
P21
P2456
P31
P496
0000-0003-0599-0069